USPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BUY now. USPH is showing solid fundamental momentum (2025/Q3 double‑digit revenue and earnings growth) and Wall Street remains constructive (JPMorgan Overweight with a $100 target even after trimming). Options positioning is extremely call-skewed (very low put activity), suggesting bullish sentiment. Technically, momentum is not strongly bullish yet (MACD still negative), but price is sitting just below the pivot (84.80) with nearby support (81.82), making the current level a reasonable immediate entry for an impatient buyer ahead of the next earnings catalyst (2026-02-26 after hours).
Price/levels: Post-market 83.87, slightly below the pivot 84.795. Immediate resistance: 87.767 (R1) then 89.603 (R2). Key supports: 81.823 (S1) then 79.987 (S2). Trend/momentum: MACD histogram -0.495 (below 0) but negatively contracting, which can indicate downside momentum is fading. RSI(6)=48.16 (neutral), consistent with consolidation rather than an extended move. Moving averages: Converging MAs suggests a coiling/indecision phase; a push back above the pivot can turn the setup more bullish quickly. Pattern-based short-term odds: Similar-pattern modeling implies ~+1.04% next day and ~+3.41% next week (with low edge over a month).
Intellectia Proprietary Trading Signals
Fundamental growth: 2025/Q3 revenue +17.32% YoY, net income +24.64% YoY, EPS +23.08% YoY.
Analyst stance: JPMorgan reiterates Overweight (constructive institutional view) with a $100 target (meaningful upside from ~84).
Event catalyst: Next earnings on 2026-02-26 (after hours) can act as a sentiment catalyst into the print.
Derivatives sentiment: Extremely low put participation (put/call ratios near zero) reflects bullish positioning.
Margins: 2025/Q3 gross margin fell to 19.73% (-3.28% YoY), which can cap multiple expansion if it persists.
Technical momentum: MACD remains below zero, so the stock is not yet in a confirmed bullish trend; a failed reclaim of the 84.8 pivot could keep it range-bound.
No fresh news: No recent week news flow, so upside may rely more on broader market tone or the next earnings setup.
Latest quarter: 2025/Q3. Revenue rose to $197.132M (+17.32% YoY). Net income increased to $7.243M (+24.64% YoY). EPS was $0.48 (+23.08% YoY). The key blemish was profitability efficiency: gross margin declined to 19.73% (-3.28% YoY). Overall, growth is strong, but margin compression is the primary item to monitor.
Recent change: On 2025-11-24, JPMorgan (Benjamin Rossi) lowered the price target to $100 from $110 while maintaining an Overweight rating after updating the model post-Q3. Wall Street pros view (pros): Overweight rating implies confidence in business trajectory and upside to fair value. Wall Street cons view (cons): Target cut (even with Overweight maintained) signals tempered expectations—likely tied to post-Q3 modeling and/or margin considerations. Ownership/trading color: Hedge funds and insiders are both reported neutral (no significant trend). Politicians/congress: No recent congress trading data available in the last 90 days; no noted politician activity.
